The briefing
Australia’s Therapeutic Goods Administration approved NIKTIMVO (axatilimab) for chronic graft-versus-host disease after failure of at least two prior systemic therapies in patients aged six and older weighing at least 40 kg. The decision followed a Priority Review pathway, expanding options for difficult-to-treat cGVHD.
Original headline
New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]